{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:05:31Z","timestamp":1787069131417,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.radonc.2020.09.053","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T22:07:59Z","timestamp":1602022079000},"page":"207-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Dose\u2013response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-626X","authenticated-orcid":false,"given":"Rebecca G.","family":"Levin-Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrinivasa K.","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Aghdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3107-6705","authenticated-orcid":false,"given":"Constantine","family":"Mantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7204-3777","authenticated-orcid":false,"given":"Alan J.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Napieralska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Namysl-Kaletka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Prionas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Bagshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Buyyounouski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4705-6629","authenticated-orcid":false,"given":"Minsong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nzhde","family":"Agazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Kupelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-1986","authenticated-orcid":false,"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-657X","authenticated-orcid":false,"given":"Osama","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon A.","family":"Mahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0553-7520","authenticated-orcid":false,"given":"Paul C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-992X","authenticated-orcid":false,"given":"Jesus","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shabsovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sartajdeep","family":"Kahlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Nickols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-5786","authenticated-orcid":false,"given":"Donald B.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.09.053_b0005","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: Prostate Cancer version 2.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed June 2, 2020."},{"key":"10.1016\/j.radonc.2020.09.053_b0010","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fonc.2012.00081","article-title":"Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer","volume":"2","author":"Parthan","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0360-3016(02)03828-2","article-title":"How low is the alpha\/beta ratio for prostate cancer?","volume":"55","author":"Wang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is \u03b1\/\u03b2 for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0030","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijrobp.2020.01.010","article-title":"Diminishing returns from ultrahypofractionated radiation therapy for prostate cancer","volume":"107","author":"Vogelius","year":"2020","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0040","first-page":"349","article-title":"Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis","volume":"4","author":"Malouff","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.radonc.2020.09.053_b0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20471","article-title":"Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the United States","volume":"3","author":"Mahase","year":"2020","journal-title":"JAMA Netw open"},{"key":"10.1016\/j.radonc.2020.09.053_b0050","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ijrobp.2019.07.008","article-title":"SBRT for localized prostate cancer: is it ready for take-off?","volume":"105","author":"Mitin","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0055","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0060","first-page":"897","article-title":"Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer","volume":"1","author":"Kalbasi","year":"2015","journal-title":"JAMAOncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0065","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.eururo.2011.08.029","article-title":"Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes","volume":"60","author":"Zelefsky","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2020.09.053_b0070","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0075","doi-asserted-by":"crossref","unstructured":"Michalski JM, Moughan J, Purdy J, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol 2018;4:e180039-e180039. doi:10.1001\/jamaoncol.2018.0039.","DOI":"10.1001\/jamaoncol.2018.0039"},{"key":"10.1016\/j.radonc.2020.09.053_b0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0085","first-page":"1","article-title":"Early tolerance and tumor control outcomes with high-dose ultrahypofractionated radiation therapy for prostate cancer","author":"Zelefsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.12.020","article-title":"Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials","volume":"118","author":"Musunuru","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2018.03.005","article-title":"Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials","volume":"127","author":"Alayed","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0100","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0105","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijrobp.2019.01.092","article-title":"Outcomes of a dose-escalated stereotactic body radiation phase 1 trial for patients with low- and intermediate-risk prostate cancer","volume":"104","author":"Potters","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0110","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0115","doi-asserted-by":"crossref","unstructured":"Kothari G, Loblaw A, Tree AC, et al. Stereotactic body radiotherapy for primary prostate cancer. Technol Cancer Res Treat 2018;17:1533033818789633-1533033818789633. doi:10.1177\/1533033818789633.","DOI":"10.1177\/1533033818789633"},{"key":"10.1016\/j.radonc.2020.09.053_b0120","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0125","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ijrobp.2019.06.2539","article-title":"Multi-institutional analysis of prostate-specific antigen kinetics after stereotactic body radiation therapy","volume":"105","author":"Jiang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0130","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ijrobp.2005.07.006","article-title":"PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis","volume":"64","author":"Ray","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0135","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.urology.2006.08.1056","article-title":"Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure","volume":"68","author":"Ray","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2020.09.053_b0140","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.prro.2015.11.002","article-title":"SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer","volume":"6","author":"Kishan","year":"2016","journal-title":"Pr Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0145","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0150","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.radonc.2012.10.006","article-title":"Bioeffect modeling and equieffective dose concepts in radiation oncology\u2013terminology, quantities and units","volume":"105","author":"Bentzen","year":"2012","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0155","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0090-4295(99)00346-5","article-title":"Post-treatment PSA \u22640.2 ng\/ml defines disease freedom after radiotherapy for prostate cancer using modern techniques","volume":"54","author":"Critz","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2020.09.053_b0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijrobp.2013.10.010","article-title":"Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival","volume":"88","author":"Lo","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0165","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.053_b0170","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/annonc\/mds001","article-title":"Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer","volume":"23","author":"Bian","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0175","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1200\/JCO.2016.34.15_suppl.5021","article-title":"Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503\/NCT00104741)","volume":"34","author":"Dubray","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0180","first-page":"4189","article-title":"Dose-escalated radiation therapy with and without short-course androgen deprivation for intermediate-risk prostate cancer","volume":"34","author":"Schreiber","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2020.09.053_b0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fonc.2014.00321","article-title":"Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations","volume":"4","author":"Fuller","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0190","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2014.00301","article-title":"Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0195","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.053_b0200","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020308288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020308288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:14:57Z","timestamp":1759122897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020308288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":40,"alternative-id":["S0167814020308288"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.09.053","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose\u2013response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.09.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}